More standing time was associated with less overweight and impaired glucose tolerance, but the results didn't hold after adjustment.
Meta-analysis shows that use of medication is associated with an 18% lower risk.
Cancer-specific and overall survival is decreased in men with intermediate-risk versus low-risk tumors.
Overweight or obese patients treated with targeted therapy for metastatic clear-cell renal cell carcinoma found to live longer.
In a study of 4,736 patients with metastatic renal cell carcinoma, use of the drugs was associated with a nearly 22% decreased risk of death.